Literature DB >> 11395308

Potential (18)F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase.

T A Bonasera1, G Ortu, Y Rozen, R Krais, N M Freedman, R Chisin, A Gazit, A Levitzki, E Mishani.   

Abstract

As PET candidate tracers for EGFr-TK, five 4-(anilino)quinazoline derivatives, each fluorinated in the aniline moiety, were prepared. Each was tested in vitro for inhibition of EGFr autophosphorylation in A431 cell line. The leading compounds were then radiolabeled with (18)F and cell binding experiments, biodistribution and PET studies in A431 tumor-bearing mice were performed. Metabolic studies were carried out in a mice control group. From our results, we concluded that while in vitro experiments indicates efficacy of 4-(anilino)quinazoline compounds, kinetic factors and rapid blood clearance make them unsuitable as tracers for nuclear medicine imaging of EGFr-TK.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11395308     DOI: 10.1016/s0969-8051(01)00200-1

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  19 in total

Review 1.  Positron emission tomography (PET): expanding the horizons of oncology drug development.

Authors:  Lisa A Hammond; Louis Denis; Umber Salman; Paul Jerabek; Charles R Thomas; John G Kuhn
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

2.  Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT.

Authors:  Hsin Hsien Yeh; Kazuma Ogawa; Julius Balatoni; Uday Mukhapadhyay; Asutosh Pal; Carlos Gonzalez-Lepera; Aleksandr Shavrin; Suren Soghomonyan; Leo Flores; Daniel Young; Andrei Y Volgin; Amer M Najjar; Victor Krasnykh; William Tong; Mian M Alauddin; Juri G Gelovani
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-10       Impact factor: 11.205

3.  Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET.

Authors:  Maria A Pantaleo; Eyal Mishani; Cristina Nanni; Lorena Landuzzi; Stefano Boschi; Giordano Nicoletti; Samar Dissoki; Paola Paterini; Pier Poalo Piccaluga; Filippo Lodi; Pier-Luigi Lollini; Stefano Fanti; Guido Biasco
Journal:  Mol Imaging Biol       Date:  2010-12       Impact factor: 3.488

4.  Radiosynthesis and initial in vitro evaluation of [18F]F-PEG6-IPQA--a novel PET radiotracer for imaging EGFR expression-activity in lung carcinomas.

Authors:  Ashutosh Pal; Julius A Balatoni; Uday Mukhopadhyay; Kazuma Ogawa; Carlos Gonzalez-Lepera; Aleksandr Shavrin; Andrei Volgin; William Tong; Mian M Alauddin; Juri G Gelovani
Journal:  Mol Imaging Biol       Date:  2011-10       Impact factor: 3.488

5.  Metabolic stability of 6,7-dialkoxy-4-(2-, 3- and 4-[18F]fluoroanilino)quinazolines, potential EGFR imaging probes.

Authors:  Neil Vasdev; Peter N Dorff; James P O'Neil; Frederick T Chin; Stephen Hanrahan; Henry F VanBrocklin
Journal:  Bioorg Med Chem       Date:  2011-03-21       Impact factor: 3.641

6.  18F-Labeled Pyrido[3,4-d]pyrimidine as an Effective Probe for Imaging of L858R Mutant Epidermal Growth Factor Receptor.

Authors:  Hiroyuki Kimura; Haruka Okuda; Masumi Ishiguro; Kenji Arimitsu; Akira Makino; Ryuichi Nishii; Anna Miyazaki; Yusuke Yagi; Hiroyuki Watanabe; Ikuo Kawasaki; Masahiro Ono; Hideo Saji
Journal:  ACS Med Chem Lett       Date:  2017-03-20       Impact factor: 4.345

7.  Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors.

Authors:  Helen Su; Yann Seimbille; Gregory Z Ferl; Claudia Bodenstein; Barbara Fueger; Kevin J Kim; Yu-Tien Hsu; Steven M Dubinett; Michael E Phelps; Johannes Czernin; Wolfgang A Weber
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-02-01       Impact factor: 9.236

Review 8.  Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics.

Authors:  Orit Jacobson; Xiaoyuan Chen
Journal:  Pharmacol Rev       Date:  2013-09-24       Impact factor: 25.468

9.  (124)I-iodopyridopyrimidinone for PET of Abl kinase-expressing tumors in vivo.

Authors:  Mikhail Doubrovin; Tatiana Kochetkova; Elmer Santos; Darren R Veach; Peter Smith-Jones; Nagavarakishore Pillarsetty; Julius Balatoni; William Bornmann; Juri Gelovani; Steven M Larson
Journal:  J Nucl Med       Date:  2010-01       Impact factor: 10.057

Review 10.  Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities.

Authors:  Eyal Mishani; Galith Abourbeh; Martin Eiblmaier; Carolyn J Anderson
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.